Clinical Trials

A clinical trial has evaluated S-Methyl-L-cysteine in healthy individuals, focusing on dietary biomarker assessment, dose-response relationships, and chemopreventive profiling rather than targeting a specific disease condition. Sponsored by an academic entity, Chalmers University of Technology, this completed study operated under an unassigned phase status (Not Applicable). Overall, clinical evaluation of the compound remains centered on establishing physiological dietary biomarkers in human cohorts.

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT05073523 Completed
Healthy
Chalmers University of Technology
2021-09-27 Not Applicable

(data from https://clinicaltrials.gov, updated on 2024-05-22)

Check the S-Methyl-L-cysteine product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

S-Methyl-L-cysteine is a bioactive organosulfur compound that modulates intracellular metabolic pathways by enhancing antioxidant enzyme activity and scavenging reactive oxygen species, thereby reducing carcinogen-induced cellular damage and inhibiting malignant transformation. This chemopreventive mechanism supports its evaluation in healthy human subjects, where dietary biomarker studies aim to establish dose-response relationships and monitor physiological organosulfur utilization.

Appendix RUO and cGMP Quality Standards

Quality Dimension RUO (Research Use Only) cGMP (Current Good Manufacturing Practice)
Clinical Applicability Prohibited in human clinical trials or medical diagnostics. Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status Non-regulated grade; exempt from drug manufacturing laws. Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment Unclassified analytical or research laboratories. Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control Basic purity and activity testing. Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation Basic equipment calibration; no process validation required. Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance Vendor self-declared without required formal QMS. Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact High risk of IND rejection if used as a critical raw material. Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).

Jump to

Note: Technical data last updated: Sep 1, 2026.